Maccura BiotechnologyLtd Valuation

Q: What is the Fair Price of 300463 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

300463 (CN¥11.42) is trading below our estimate of [[fair value]] (CN¥43.98)

Is 300463 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 300463 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 300463 (CN¥11.42) is trading below our estimate of fair value (CN¥43.98)

Significantly Below Fair Value: 300463 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 300463?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for 300463. This is calculated by dividing 300463's market cap by their current preferred multiple.
What is 300463's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	CN¥6.93b

300463 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	2.5x
Enterprise Value/EBITDA	10.5x
PEG Ratio	0.8x

Price to Earnings Ratio vs Peers

How does 300463's PE Ratio compare to its peers?

The above table shows the PE ratio for 300463 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	26.1x
603108 Shanghai Runda Medical Technology	33.9x	55.9%	CN¥7.3b
688046 GemPharmatech	24.9x	23.6%	CN¥3.9b
301333 R&G PharmaStudies	23.8x	20.4%	CN¥3.7b
688315 Novogene	21.9x	19.1%	CN¥4.0b
300463 Maccura BiotechnologyLtd	20.4x	25.4%	CN¥6.9b

Price-To-Earnings vs Peers: 300463 is good value based on its Price-To-Earnings Ratio (20.4x) compared to the peer average (26.1x).

Price to Earnings Ratio vs Industry

How does 300463's PE Ratio compare vs other companies in the Asian Life Sciences Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	27.9%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	27.9%
	n/a	n/a	n/a

No more companies

Price-To-Earnings vs Industry: 300463 is good value based on its Price-To-Earnings Ratio (20.4x) compared to the Asian Life Sciences industry average (23.9x).

Price to Earnings Ratio vs Fair Ratio

What is 300463's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

300463 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	20.4x
Fair PE Ratio	25.8x

Price-To-Earnings vs Fair Ratio: 300463 is good value based on its Price-To-Earnings Ratio (20.4x) compared to the estimated Fair Price-To-Earnings Ratio (25.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.